Modra Pharmaceuticals is focused on revolutionizing taxane therapies, which are critical in cancer treatment, by developing boosted oral formulations that enhance the delivery, bioavailability, and tolerability of these drugs. Their proprietary approach addresses the significant challenges associated with traditional intravenous (IV) administration of taxanes, such as docetaxel and paclitaxel, which are often linked to severe side effects and require frequent hospital visits. Modra's lead product, ModraDoc006/r, combines an optimized oral formulation of docetaxel with ritonavir, a boosting agent that enhances the drug's systemic and intratumoral exposure. This innovative strategy not only aims to improve patient comfort by allowing at-home administration but also seeks to reduce the toxicities commonly associated with IV formulations.

The technology behind Modra's products is designed to overcome the inherent difficulties of delivering taxanes orally, which include their low water solubility and rapid metabolism by enzymes like CYP3A4. By eliminating harmful excipients found in IV formulations and utilizing a booster to enhance drug levels, Modra Pharmaceuticals is paving the way for a new standard of care in cancer treatment. Their commitment to improving the quality of life for cancer patients is evident in their ongoing clinical trials and the potential for further development of additional boosted oral taxanes, such as ModraPac005/r for paclitaxel.

Netherlands

Modra (Modulated Oral Drug Absorption) Pharmaceuticals B.V. is a spin-out from two internationally acclaimed centers of excellence in oncology, the ‘Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)’ and the MC Slotervaart (Slotervaart) in Amsterdam. Modra Pharmaceuticals is a clinical stage company that develops new treatment paradigms by enabling oral bioavailability of existing anticancer drugs, “the iv to oral switch”, to improve cancer therapy and supportive care. Modra Pharmaceuticals has several products in preclinical and clinical development including oral formulations of docetaxel and paclitaxel.

Modra Pharmaceuticals

Company Details